Site-specific albumination of a therapeutic protein with multi-subunit to prolong activity in vivo

Journal of Controlled Release

Volumn 207, Issue , 2015, Pages 93-100

  Lim, Sung In ^a   Hahn, Young S ^b   Kwon, Inchan ^a,c  

^a University of Virginia   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c Gwangju Institute of Science and Technology (GIST)   (South Korea)

Author keywords

Non natural amino acid; Site specific albumination; Strain promoted azide alkyne cycloaddition; Therapeutic protein; Urate oxidase

Indexed keywords

AMINO ACIDS; HYDROCARBONS; MAMMALS;

AZIDE-ALKYNE CYCLOADDITION; NON NATURAL AMINO ACIDS; SITE-SPECIFIC; THERAPEUTIC PROTEIN; URATE OXIDASE;

PROTEINS;

ALKYNE; AZIDE; HUMAN SERUM ALBUMIN; HYBRID PROTEIN; PHENYLALANINE; URATE OXIDASE; ALB PROTEIN, HUMAN; FUNGAL PROTEIN; SERUM ALBUMIN;

ALBUMINATION; ANIMAL EXPERIMENT; ANION EXCHANGE CHROMATOGRAPHY; AREA UNDER THE CURVE; ARTICLE; CIRCULAR DICHROISM; CONJUGATION; CONTROLLED STUDY; CYCLOADDITION; DRUG ELIMINATION; DRUG HALF LIFE; ENZYME ACTIVITY; FEMALE; GEL PERMEATION CHROMATOGRAPHY; HYPERURICEMIA; IN VIVO STUDY; ION EXCHANGE CHROMATOGRAPHY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN MODIFICATION; PROTEIN SECONDARY STRUCTURE; PROTEIN SYNTHESIS; STOICHIOMETRY; STRAIN PROMOTED AZIDE ALKYNE CYCLOADDITION; WILD TYPE; ANIMAL; ASPERGILLUS FLAVUS; BIOSYNTHESIS; C57BL MOUSE; CHEMISTRY; DRUG STABILITY; ENZYME STABILITY; ENZYMOLOGY; GENETICS; HALF LIFE TIME; INTRAVENOUS DRUG ADMINISTRATION; PROTEIN ENGINEERING;

ANIMALS; AREA UNDER CURVE; ASPERGILLUS FLAVUS; DRUG STABILITY; ENZYME STABILITY; FEMALE; FUNGAL PROTEINS; HALF-LIFE; INJECTIONS, INTRAVENOUS; MICE, INBRED C57BL; PROTEIN ENGINEERING; RECOMBINANT FUSION PROTEINS; SERUM ALBUMIN; URATE OXIDASE;

EID: 84927666592     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2015.04.004     Document Type: Article

References (78)

1. R.S. Aggarwal What's fueling the biotech engine - 2012 to 2013 Nat. Biotechnol. 32 1 2014 32 39
2. S. Kontos, and J.A. Hubbell Drug development: longer-lived proteins Chem. Soc. Rev. 41 7 2012 2686 2695
3. B. Elsadek, and F. Kratz Impact of albumin on drug delivery - new applications on the horizon J. Control. Release 157 1 2012 4 28
4. F. Kratz, and B. Elsadek Clinical impact of serum proteins on drug delivery J. Control. Release 161 2 2012 429 445
5. D. Sleep, J. Cameron, and L.R. Evans Albumin as a versatile platform for drug half-life extension Biochim. Biophys. Acta 1830 12 2013 5526 5534
6. A. Duttaroy, P. Kanakaraj, B.L. Osborn, H. Schneider, O.K. Pickeral, C. Chen, G. Zhang, S. Kaithamana, M. Singh, R. Schulingkamp, D. Crossan, J. Bock, T.E. Kaufman, P. Reavey, M. Carey-Barber, S.R. Krishnan, A. Garcia, K. Murphy, J.K. Siskind, M.A. McLean, S. Cheng, S. Ruben, C.E. Birse, and O. Blondel Development of a long-acting insulin analog using albumin fusion technology Diabetes 54 1 2005 251 258
7. S. Ikuta, V.T. Chuang, Y. Ishima, K. Nakajou, M. Furukawa, H. Watanabe, T. Maruyama, and M. Otagiri Albumin fusion of thioredoxin - the production and evaluation of its biological activity for potential therapeutic applications J. Control. Release 147 1 2010 17 23
8. C.H. Joung, J.Y. Shin, J.K. Koo, J.J. Lim, J.S. Wang, S.J. Lee, H.K. Tan, S.L. Kim, and S.M. Lim Production and characterization of long-acting recombinant human albumin-EPO fusion protein expressed in CHO cell Protein Expr. Purif. 68 2 2009 137 145
9. B.L. Osborn, L. Sekut, M. Corcoran, C. Poortman, B. Sturm, G. Chen, D. Mather, H.L. Lin, and T.J. Parry Albutropin: a growth hormone-albumin fusion with improved pharmacokinetics and pharmacodynamics in rats and monkeys Eur. J. Pharmacol. 456 1-3 2002 149 158
10. J. Rosenstock, J. Reusch, M. Bush, F. Yang, and M. Stewart Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing Diabetes Care 32 10 2009 1880 1886
11. G.M. Subramanian, M. Fiscella, A. Lamouse-Smith, S. Zeuzem, and J.G. McHutchison Albinterferon alpha-2b: a genetic fusion protein for the treatment of chronic hepatitis C Nat. Biotechnol. 25 12 2007 1411 1419
12. A.A. Cordes, C.W. Platt, J.F. Carpenter, and T.W. Randolph Selective domain stabilization as a strategy to reduce fusion protein aggregation J. Pharm. Sci. 101 4 2012 1400 1409
13. S.R. Schmidt Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges 2013 Wiley New Jersey 95
14. H.L. Zhao, C. Xue, Y. Wang, B. Sun, X.Q. Yao, and Z.M. Liu Elimination of the free sulfhydryl group in the human serum albumin (HSA) moiety of human interferon-alpha2b and HSA fusion protein increases its stability against mechanical and thermal stresses Eur. J. Pharm. Biopharm. 72 2 2009 405 411
15. I. Kwon, P. Wang, and D.A. Tirrell Design of a bacterial host for site-specific incorporation of p-bromophenylalanine into recombinant proteins J. Am. Chem. Soc. 128 36 2006 11778 11783
16. T. Plass, S. Milles, C. Koehler, C. Schultz, and E.A. Lemke Genetically encoded copper-free click chemistry Angew. Chem. Int. Ed. Engl. 50 17 2011 3878 3881
17. J.L. Seitchik, J.C. Peeler, M.T. Taylor, M.L. Blackman, T.W. Rhoads, R.B. Cooley, C. Refakis, J.M. Fox, and R.A. Mehl Genetically encoded tetrazine amino acid directs rapid site-specific in vivo bioorthogonal ligation with trans-cyclooctenes J. Am. Chem. Soc. 134 6 2012 2898 2901
18. L. Wang, A. Brock, B. Herberich, and P.G. Schultz Expanding the genetic code of Escherichia coli Science 292 5516 2001 498 500
19. Q. Wang, T.R. Chan, R. Hilgraf, V.V. Fokin, K.B. Sharpless, and M.G. Finn Bioconjugation by copper(I)-catalyzed azide-alkyne [3 + 2] cycloaddition J. Am. Chem. Soc. 125 11 2003 3192 3193
20. P.R. Chen, D. Groff, J. Guo, W. Ou, S. Cellitti, B.H. Geierstanger, and P.G. Schultz A facile system for encoding unnatural amino acids in mammalian cells Angew. Chem. Int. Ed. Engl. 48 22 2009 4052 4055
21. S.M. Hancock, R. Uprety, A. Deiters, and J.W. Chin Expanding the genetic code of yeast for incorporation of diverse unnatural amino acids via a pyrrolysyl-tRNA synthetase/tRNA pair J. Am. Chem. Soc. 132 42 2010 14819 14824
22. M. King, and A. Wagner Developments in the field of bioorthogonal bond forming reactions-past and present trends Bioconjug. Chem. 25 5 2014 825 839
23. C.D. Spicer, and B.G. Davis Selective chemical protein modification Nat. Commun. 5 2014 4740
24. H. Cho, T. Daniel, Y.J. Buechler, D.C. Litzinger, Z. Maio, A.M. Putnam, V.S. Kraynov, B.C. Sim, S. Bussell, T. Javahishvili, S. Kaphle, G. Viramontes, M. Ong, S. Chu, G.C. Becky, R. Lieu, N. Knudsen, P. Castiglioni, T.C. Norman, D.W. Axelrod, A.R. Hoffman, P.G. Schultz, R.D. DiMarchi, and B.E. Kimmel Optimized clinical performance of growth hormone with an expanded genetic code Proc. Natl. Acad. Sci. U. S. A. 108 22 2011 9060 9065
25. A. Deiters, T.A. Cropp, D. Summerer, M. Mukherji, and P.G. Schultz Site-specific PEGylation of proteins containing unnatural amino acids Bioorg. Med. Chem. Lett. 14 23 2004 5743 5745
26. S.B. Sun, P.G. Schultz, and C.H. Kim Therapeutic applications of an expanded genetic code Chembiochem 15 12 2014 1721 1729
27. F. Tian, Y. Lu, A. Manibusan, A. Sellers, H. Tran, Y. Sun, T. Phuong, R. Barnett, B. Hehli, F. Song, M.J. DeGuzman, S. Ensari, J.K. Pinkstaff, L.M. Sullivan, S.L. Biroc, H. Cho, P.G. Schultz, J. DiJoseph, M. Dougher, D. Ma, R. Dushin, M. Leal, L. Tchistiakova, E. Feyfant, H.P. Gerber, and P. Sapra A general approach to site-specific antibody drug conjugates Proc. Natl. Acad. Sci. U. S. A. 111 5 2014 1766 1771
28. S.I. Lim, Y. Mizuta, A. Takasu, Y.S. Hahn, Y.H. Kim, and I. Kwon Site-specific fatty acid-conjugation to prolong protein half-life in vivo J. Control. Release 170 2 2013 219 225
29. V.V. Rostovtsev, L.G. Green, V.V. Fokin, and K.B. Sharpless A stepwise huisgen cycloaddition process: copper(I)-catalyzed regioselective "ligation" of azides and terminal alkynes Angew. Chem. Int. Ed. Engl. 41 14 2002 2596 2599
30. Q. Zeng, S. Saha, L.A. Lee, H. Barnhill, J. Oxsher, T. Dreher, and Q. Wang Chemoselective modification of turnip yellow mosaic virus by Cu(I) catalyzed azide-alkyne 1,3-dipolar cycloaddition reaction and its application in cell binding Bioconjug. Chem. 22 1 2011 58 66
31. N.J. Agard, J.A. Prescher, and C.R. Bertozzi A strain-promoted [3 + 2] azide-alkyne cycloaddition for covalent modification of biomolecules in living systems J. Am. Chem. Soc. 126 46 2004 15046 15047
32. X. Ning, J. Guo, M.A. Wolfert, and G.J. Boons Visualizing metabolically labeled glycoconjugates of living cells by copper-free and fast huisgen cycloadditions Angew. Chem. Int. Ed. Engl. 47 12 2008 2253 2255
33. L. Gabison, M. Chiadmi, M. El Hajji, B. Castro, N. Colloc'h, and T. Prange Near-atomic resolution structures of urate oxidase complexed with its substrate and analogues: the protonation state of the ligand Acta Crystallogr. D Biol. Crystallogr. 66 Pt 6 2010 714 724
34. O. Bessmertny, L.M. Robitaille, and M.S. Cairo Rasburicase: a new approach for preventing and/or treating tumor lysis syndrome Curr. Pharm. Des. 11 32 2005 4177 4185
35. P.M. Navolanic, C.H. Pui, R.A. Larson, M.R. Bishop, T.E. Pearce, M.S. Cairo, S.C. Goldman, S.C. Jeha, C.B. Shanholtz, J.P. Leonard, and J.A. McCubrey Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002 Leukemia 17 3 2003 499 514
36. C. Geraths, M. Daoud-El Baba, G. Charpin-El Hamri, and W. Weber A biohybrid hydrogel for the urate-responsive release of urate oxidase J. Control. Release 171 1 2013 57 62
37. S. Jeha, and C.H. Pui Recombinant urate oxidase (rasburicase) in the prophylaxis and treatment of tumor lysis syndrome Contrib. Nephrol. 147 2005 69 79
38. A.R. Sood, L.D. Burry, and D.K. Cheng Clarifying the role of rasburicase in tumor lysis syndrome Pharmacotherapy 27 1 2007 111 121
39. N. Schlesinger, U. Yasothan, and P. Kirkpatrick Pegloticase Nat. Rev. Drug Discov. 10 1 2011 17 18
40. C. Zhang, K. Fan, H. Luo, X. Ma, R. Liu, L. Yang, C. Hu, Z. Chen, Z. Min, and D. Wei Characterization, efficacy, pharmacokinetics, and biodistribution of 5 kDa mPEG modified tetrameric canine uricase variant Int. J. Pharm. 430 1-2 2012 307 317
41. J.S. Bomalaski, F.W. Holtsberg, C.M. Ensor, and M.A. Clark Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies J. Rheumatol. 29 9 2002 1942 1949
42. C.S. Fishburn The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics J. Pharm. Sci. 97 10 2008 4167 4183
43. T. McDonnell, Y. Ioannou, and A. Rahman PEGylated drugs in rheumatology - why develop them and do they work? Rheumatology (Oxford) 53 3 2014 391 396
44. S. Freitas Dda, P.J. Spencer, R.C. Vassao, and J. Abrahao-Neto Biochemical and biopharmaceutical properties of PEGylated uricase Int. J. Pharm. 387 1-2 2010 215 222
45. H. Tian, Y. Guo, X. Gao, and W. Yao PEGylation enhancement of pH stability of uricase via inhibitive tetramer dissociation J. Pharm. Pharmacol. 65 1 2012 53 63
46. J.T. Kratzer, M.A. Lanaspa, M.N. Murphy, C. Cicerchi, C.L. Graves, P.A. Tipton, E.A. Ortlund, R.J. Johnson, and E.A. Gaucher Evolutionary history and metabolic insights of ancient mammalian uricases Proc. Natl. Acad. Sci. U. S. A. 111 10 2014 3763 3768
47. J.W. Chin, S.W. Santoro, A.B. Martin, D.S. King, L. Wang, and P.G. Schultz Addition of p-azido-l-phenylalanine to the genetic code of Escherichia coli J. Am. Chem. Soc. 124 31 2002 9026 9027
48. S.R. Bond, and C.C. Naus RF-Cloning.org: an online tool for the design of restriction-free cloning projects Nucleic Acids Res. 40 2012 W209 W213 (Web Server issue)
49. M.J. Lajoie, A.J. Rovner, D.B. Goodman, H.R. Aerni, A.D. Haimovich, G. Kuznetsov, J.A. Mercer, H.H. Wang, P.A. Carr, J.A. Mosberg, N. Rohland, P.G. Schultz, J.M. Jacobson, J. Rinehart, G.M. Church, and F.J. Isaacs Genomically recoded organisms expand biological functions Science 342 6156 2013 357 360
50. C.N. Pace, F. Vajdos, L. Fee, G. Grimsley, and T. Gray How to measure and predict the molar absorption coefficient of a protein Protein Sci. 4 11 1995 2411 2423
51. G.R. Grimsley, and C.N. Pace G.P. Taylor, Current Protocols in Protein Science 2004 Wiley New Jersey (p. Unit 3.1)
52. L. Whitmore, and B.A. Wallace Protein secondary structure analyses from circular dichroism spectroscopy: methods and reference databases Biopolymers 89 5 2008 392 400
53. J.A. Irwin, H.E. Wong, and I. Kwon Different fates of Alzheimer's disease amyloid-beta fibrils remodeled by biocompatible small molecules Biomacromolecules 14 1 2013 264 274
54. N. Sreerama, S.Y. Venyaminov, and R.W. Woody Estimation of the number of alpha-helical and beta-strand segments in proteins using circular dichroism spectroscopy Protein Sci. 8 2 1999 370 380
55. N. Sreerama, and R.W. Woody A self-consistent method for the analysis of protein secondary structure from circular dichroism Anal. Biochem. 209 1 1993 32 44
56. C. Zhang, K. Fan, X. Ma, and D. Wei Impact of large aggregated uricases and PEG diol on accelerated blood clearance of PEGylated canine uricase PLoS ONE 7 6 2012 e39659
57. B. Ahren, R.M. Baldwin, and P.J. Havel Pharmacokinetics of human leptin in mice and rhesus monkeys Int. J. Obes. Relat. Metab. Disord. 24 12 2000 1579 1585
58. J.M. Sanders, G.A. Knudsen, and L.S. Birnbaum The fate of beta-hexabromocyclododecane in female C57BL/6 mice Toxicol. Sci. 134 2 2013 251 257
59. M. Simon, R. Frey, U. Zangemeister-Wittke, and A. Pluckthun Orthogonal assembly of a designed ankyrin repeat protein-cytotoxin conjugate with a clickable serum albumin module for half-life extension Bioconjug. Chem. 24 11 2013 1955 1966
60. J.T. Andersen, B. Dalhus, J. Cameron, M.B. Daba, A. Plumridge, L. Evans, S.O. Brennan, K.S. Gunnarsen, M. Bjoras, D. Sleep, and I. Sandlie Structure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptor Nat. Commun. 3 2012 610
61. S. Ahmad, M. Gromiha, H. Fawareh, and A. Sarai ASAView: database and tool for solvent accessibility representation in proteins BMC Bioinf. 5 2004 51
62. Y. Guillaneuf, P.E. Dufils, L. Autissier, M. Rollet, D. Gigmes, and D. Bertin Radical chain end chemical transformation of SG1-based polystyrenes Macromolecules 43 1 2010 91 100
63. Y. Li, J.N. Hoskins, S.G. Sreerama, and S.M. Grayson MALDI-TOF mass spectral characterization of polymers containing an azide group: evidence of metastable ions Macromolecules 43 14 2010 6225 6228
64. J.F. Lutz, H.G. Borner, and K. Weichenhan Combining atom transfer radical polymerization and click chemistry: a versatile method for the preparation of end-functional polymers Macromol. Rapid Commun. 26 7 2005 514 518
65. J. Raynaud, C. Absalon, Y. Gnanou, and D. Taton N-heterocyclic carbene-induced zwitterionic ring-opening polymerization of ethylene oxide and direct synthesis of alpha, omega-difunctionalized poly(ethylene oxide)s and poly(ethylene oxide)-b-poly(epsilon-caprolactone) block copolymers J. Am. Chem. Soc. 131 9 2009 3201 3209
66. S. Gregoire, S. Zhang, J. Costanzo, K. Wilson, E.J. Fernandez, and I. Kwon Cis-suppression to arrest protein aggregation in mammalian cells Biotechnol. Bioeng. 111 3 2014 462 474
67. J.T. DiPiro Concepts in Clinical Pharmacokinetics fifth ed 2010 American Society of Health System Pharmacists Bethesda
68. M.J. Lajoie, S. Kosuri, J.A. Mosberg, C.J. Gregg, D. Zhang, and G.M. Church Probing the limits of genetic recoding in essential genes Science 342 6156 2013 361 363
69. P.S. Banerjee, P. Ostapchuk, P. Hearing, and I.S. Carrico Unnatural amino acid incorporation onto adenoviral (Ad) coat proteins facilitates chemoselective modification and retargeting of Ad type 5 vectors J. Virol. 85 15 2011 7546 7554
70. M.R. Fleissner, E.M. Brustad, T. Kalai, C. Altenbach, D. Cascio, F.B. Peters, K. Hideg, S. Peuker, P.G. Schultz, and W.L. Hubbell Site-directed spin labeling of a genetically encoded unnatural amino acid Proc. Natl. Acad. Sci. U. S. A. 106 51 2009 21637 21642
71. S.I. Lim, Y. Mizuta, A. Takasu, Y.H. Kim, and I. Kwon Site-specific bioconjugation of a murine dihydrofolate reductase enzyme by copper(I)-catalyzed azide-alkyne cycloaddition with retained activity PLoS ONE 9 6 2014 e98403
72. S.C. Reddington, E.M. Tippmann, and D.D. Jones Residue choice defines efficiency and influence of bioorthogonal protein modification via genetically encoded strain promoted Click chemistry Chem. Commun. (Camb.) 48 67 2012 8419 8421
73. M.R. Sherman, M.G. Saifer, and F. Perez-Ruiz PEG-uricase in the management of treatment-resistant gout and hyperuricemia Adv. Drug Deliv. Rev. 60 1 2008 59 68
74. T. Fujita, Y. Yasuda, Y. Takakura, M. Hashida, and H. Sezaki Tissue distribution of 111In-labeled uricase conjugated with charged dextrans and polyethylene glycol J. Pharmacobiodyn. 14 11 1991 623 629
75. M.G. Saifer, L.D. Williams, M.A. Sobczyk, S.J. Michaels, and M.R. Sherman Selectivity of binding of PEGs and PEG-like oligomers to anti-PEG antibodies induced by methoxyPEG-proteins Mol. Immunol. 57 2 2014 236 246
76. M.R. Sherman, L.D. Williams, M.A. Sobczyk, S.J. Michaels, and M.G. Saifer Role of the methoxy group in immune responses to mPEG-protein conjugates Bioconjug. Chem. 23 3 2012 485 499
77. J.T. Andersen, M.B. Daba, G. Berntzen, T.E. Michaelsen, and I. Sandlie Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding J. Biol. Chem. 285 7 2010 4826 4836
78. M.M. Schmidt, S.A. Townson, A.J. Andreucci, B.M. King, E.B. Schirmer, A.J. Murillo, C. Dombrowski, A.W. Tisdale, P.A. Lowden, A.L. Masci, J.T. Kovalchin, D.V. Erbe, K.D. Wittrup, E.S. Furfine, and T.M. Barnes Crystal structure of an HSA/FcRn complex reveals recycling by competitive mimicry of HSA ligands at a pH-dependent hydrophobic interface Structure 21 11 2013 1966 1978